People to know in Greater Louisville's construction sector: 2025
Louisville Business First is spotlighting 20 professionals working in the region's construction and related industries in our latest People to Know feature.
Even with a worrisome outlook for the U.S. economy, Louisville has a handful of exciting construction projects either under way or just completed.
LBF Reporter Piper Hansen had a close-up look at one recently with a tour of the UofL Health's $186 million addition to the Downtown UofL Hospital, which is still under construction. The seven-story, 200,000-square-foot tower will include clinical space, operating rooms, a new lobby, gift shop, chapel, and waiting area among other features.
LBF also reported new details on the recently completed new luxury hotel, Hotel Bourré Bonne, which opened at 143 W. Market St. last week. The $80 million hotel offers 168 rooms across five stories and features two restaurants, as we reported.
It's projects like these that help Louisville's economy grow and evolve. And they wouldn't be possible without the professionals in the local construction industry. With that, LBF is spotlighting 20 professionals working in the region's construction and related industries in our next People to Know feature. Several honorees came from nominations from peers and colleagues, and others were selected by Business First editors.
Profiles on each of the People to Know will be online and in print May 30. Here are the 20 honorees:
Lauren Aberili, Buffalo Construction
Nicholas Morris, Buzick Construction, Inc.
Seth Cook, Calhoun Construction Services
Travis Foxx, Cornerstone Engineering
Matt Zaryk, Denton Floyd Real Estate Group/Forge Construction
Andy Joy, East & Westbrook Construction
Carolyn Banet, Flynn Brothers
Robert Kochansky, LDG Development
Ricky George, Link Electric Co
Michael Bryant, LPX Group/PACE Contracting
Erik Dunham, Marian Construction
Micah McRae, McRae Enterprises
Kristy Inmon, Miranda Construction
Rich Heareth, Perfection Builders
Amy Dempsey Wagner, Reflections of You, by Amy
Christopher Manzo, SNDBX Design Collaborative
Haley Burge, Spray-Tec, Inc.
Ryan Jones, Weber Group
Cindy Mason, Wehr Construction
Tom Young, Whittenberg Construction
People to Know connects the Louisville-area business community with influential people in key roles that are crucial to their businesses. People in this feature run the gamut from behind-the-scenes all-stars to key leaders to up-and-comers in the featured industry.
We've done similar lists for those working in sectors such as health care, real estate and accounting.
Click on the links below to nominate for other People to Know features. It's free to nominate and self-nominations are welcome:
• 20 People to Know: Banking — Deadline April, 25
• 20 People to Know: Automotive — Deadline June, 6
• 20 People to Know: Real Estate — Deadline July 25
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
3 days ago
- Newsweek
Trump Puts Iran Nuclear Deal in Doubt, Raising Risk of War
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump has signaled diminishing confidence in reaching a nuclear agreement with Iran, raising new concerns about the possibility of military conflict in the region. In a podcast interview released on Wednesday, Trump said he's "getting more and more—less confident" about securing a deal. The remarks come at a sensitive moment, with both nations returning to the negotiating table but casting doubt on each other's intentions. Though talks are scheduled, mutual distrust and competing demands continue to cloud the path to any lasting agreement. Newsweek has reached out to the White House and Iran's foreign ministry for comment. Why It Matters While the United States and Iran have agreed to resume nuclear talks, President Trump's increasingly doubtful tone and Tehran's escalating rhetoric are raising concerns about whether diplomacy can succeed. With American military assets and allies stationed across a volatile region, even the perception of failed negotiations could heighten the risk of miscalculation. The renewed uncertainty marks a critical test of Trump's foreign policy strategy, especially following his withdrawal from the 2015 nuclear agreement during his first term. President Donald Trump gestures after speaking at Fort Bragg, Tuesday, June 10, 2025, in Fort Bragg, N.C. President Donald Trump gestures after speaking at Fort Bragg, Tuesday, June 10, 2025, in Fort Bragg, N.C. Alex Brandon/AP Photo What to Know Trump's comments on the "Pod Force One" podcast offered a stark contrast to his earlier optimism. Asked if he believed Iran would agree to end uranium enrichment, Trump said, "I did think so, and I'm getting more and more—less confident about it." On the negotiations, he said: "Something happened to them... I am much less confident of a deal being made." Military Options While saying that the United States will not allow Iran to develop a nuclear weapon, Trump said it would be "nicer" to avoid war. Nonetheless, the Pentagon is preparing for alternate scenarios. General Michael Kurilla, the outgoing head of U.S. Central Command, told lawmakers on Tuesday that strike plans had been submitted to the White House in the event negotiations collapse. Iran Issues Its Own Warnings Iran continues to say its nuclear activities are focused on peaceful purposes such as energy production. However, Defense Minister General Aziz Nasirzadeh issued a pointed threat, warning that Iranian forces would target U.S. bases across the region if hostilities begin. "If a conflict is imposed on us... all U.S. bases are within our reach," he said. In this photo provided Monday, Jan. 13, 2025, by the Iranian Army, Iranian Defense Minister Gen. Aziz Nasirzadeh, right, speaks with the army commander Gen. Abdolrahim Mousavi in a ceremony to deliver domestically-built drones to... In this photo provided Monday, Jan. 13, 2025, by the Iranian Army, Iranian Defense Minister Gen. Aziz Nasirzadeh, right, speaks with the army commander Gen. Abdolrahim Mousavi in a ceremony to deliver domestically-built drones to the army. More Iranian Army/AP Photo Trump has continued to press for a tougher nuclear deal, saying that previous frameworks gave Iran too much leeway. Since exiting the 2015 international agreement (JCPOA) in 2018, his administration has sought stricter terms that would impose broader limits on Iran's nuclear activity—particularly its uranium enrichment—and regional behavior. What People Are Saying U.S. President Donald Trump: "I did think so, and I'm getting more and more—less confident about it. It would be nicer to do it without warfare, without people dying." Iran Defense Minister General Aziz Nasirzadeh: "All U.S. bases are within our reach and we will boldly target them in host countries." What Happens Next Talks are set to resume later this week, with Trump indicating negotiations could begin Thursday and Iran pointing to Sunday in Oman. Tehran is expected to deliver a counter-proposal to the U.S. offer it previously rejected. While both sides remain at the table, the growing strain and threats of military action have cast a shadow over the talks, raising the possibility that failure could bring the two nations closer to open conflict.
Yahoo
4 days ago
- Yahoo
Major Food Supplier That Supports Whole Foods, Walmart and Target Hit by Cyberattack—Here's What to Know
Major Food Supplier That Supports Whole Foods, Walmart and Target Hit by Cyberattack—Here's What to Know originally appeared on Parade. In our increasingly digital world, it's becoming harder and harder to distinguish between what's real and what's been generated by some all-powerful computer that feeds off of the data we give it to inform us of things we could probably find out by doing our own independent research. Sure, it's incredibly fast and in some cases democratizing, but is it really better to rely on software and programming to tell us everything we need to know in less time than it takes to warm up a slice of pizza? What about, I don't know, just picking up a book? We don't even know ourselves anymore. Am I AI? Am I dancer? The answer remains inconclusive. 😋😋SIGN UP to get delicious recipes, handy kitchen hacks & more in our daily Pop Kitchen newsletter🍳🍔 Regardless, it's been said that once a fuse is lit, it can no longer be put out, and it appears my friends that we're only seeing the beginnings of the flame. With most systems being digitized entirely, or at least backed up to some version of the cloud, without the right security and protocols in place, the information stored in these seemingly invisible data centers is ripe for cyber criminals to have a field day. Add in an ease to the rules in place that protect us from such attacks, and it's only a matter of time before catastrophe strikes. In the case of national food supplier United Natural Foods, that's exactly what Rhode Island-based food distributor shared in a June 9 filing with the Securities and Exchange Commission that they had discovered unauthorized activity on internal networks, causing major disruptions to their supply chain and ability to fulfill orders. As one of the largest U.S. grocery distributors of organic goods and healthier food options, United Natural supplies chains such as Whole Foods, Walmart, and Target, all of which are considered major retailers by consumers. To stop the attack, the company has taken certain systems offline and is investigating the source of the threat; however, it does anticipate that the incident will continue to affect its ability to fulfill orders. While we can't say for certain that we'll see any empty shelves, attacks like these are becoming increasingly more common, and there is the potential for it to disrupt our supply chain long-term. Not saying the solution is to go back to paper ledgers and filing cabinets, but maybe it would be a good idea to stop worrying about people exercising their right to peacefully organize, and more time actually protecting each other. Just a Food Supplier That Supports Whole Foods, Walmart and Target Hit by Cyberattack—Here's What to Know first appeared on Parade on Jun 10, 2025 This story was originally reported by Parade on Jun 10, 2025, where it first appeared.
Business Wire
02-06-2025
- Business Wire
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced initial Phase 1 safety and efficacy data from the Phase 1/2 Agni-01 multicenter study of OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma (NCT06060613). These data, summarized below, will be presented in a rapid oral presentation (abstract 9517) delivered by Jason A. Chesney, M.D., Ph.D., Director and Chief Administrative Officer of UofL Health – Brown Cancer Center/Oncology Service Line at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Obsidian is also presenting a poster for abstract 9519 summarizing translational data from the Phase 1 first-in-human single-center study of OBX-115 (NCT05470283, enrollment completed) in ICI-resistant advanced melanoma. Summary of OBX-115 Safety and Efficacy Data (March 26, 2025 data cutoff): Advancing a More Patient-centric TIL Cell Therapy Regimen in Heavily Pre-treated Advanced Melanoma Patient Population Patients had disease that was predominantly ICI primary-resistant, with a median of 4 (range, 1–6) lines of prior systemic therapy, including a median of 2 (1–5) lines of prior ICI therapy (n=11). 10 patients received low-dose lymphodepletion (approximately 50% less Cyclophosphamide relative to non-engineered TIL), including 1 in the outpatient setting. Acetazolamide (ACZ) redosing following initial OBX-115 infusion to drive re-activation of OBX-115 cells was tolerable and safe enough to administer at home. OBX-115 Continues to Deliver Positively Differentiated Safety Profile Relative to Non-engineered TIL; No IL2, No Treatment-related Mortality: No dose-limiting toxicities were observed at any dose level. No Grade 4 or higher nonhematologic treatment-related adverse events (TRAEs) were reported; 5 patients experienced limited Grade 3 nonhematologic TRAEs. No confirmed events of cytokine release syndrome or infusion-related reaction higher than Grade 2; no capillary leak syndrome or immune effector cell-associated neurotoxicity syndrome were reported. No treatment-related ICU transfer, no treatment-related mortality. OBX-115 Maintains Consistent Efficacy Profile Without IL2 and With Low-dose Lymphodepletion in Anti-PD-1-resistant Advanced Melanoma; Dose Level 3 (RP2D) To Be Further Explored in Phase 2 Encouraging efficacy profile observed at the RP2D (n=6) 66.7% ORR, including 1 confirmed CR and 3 confirmed PRs (investigator-assessed RECIST 1.1 criteria) Durable clinical benefit, including 3 of 4 responses ongoing at week 24 / data cutoff (median duration of response not reached) 100% disease control rate, defined as stable disease or better for ≥12 weeks post-infusion 36.4% objective response rate (ORR) across all dose levels (n=11) Majority had reduction in tumor burden reduction: 83% at RP2D; 73% across all dose levels. Dr. Chesney commented, 'It is very encouraging to see the promising safety and efficacy profile for OBX-115, now observed in the Agni-01 multicenter study. As a highly differentiated, IL2-sparing TIL cell therapy that is compatible with low-dose lymphodepletion, OBX-115 has the potential to transform the treatment landscape and broaden the eligible population for patients with high unmet need.' 'The exciting results from OBX-115 in ICI-resistant advanced melanoma further indicate that OBX-115 has promising therapeutic potential, and that ACZ redosing is well-tolerated and has the potential to re-activate and re-expand persistent OBX-115 TIL,' commented Parameswaran Hari, M.D., Chief Development Officer of Obsidian. 'We look forward to exploring the go-forward melanoma RP2D in Phase 2, and continuing to evaluate OBX-115 in a Phase 1 cohort of patients with advanced non-small cell lung cancer, where we believe the potential impact from an IL2-sparing TIL cell therapy is clinically significant and may expand patient eligibility.' Obsidian is actively enrolling patients with advanced or metastatic melanoma and non-small cell lung cancer (NSCLC) at multiple sites in its ongoing Phase 1/2 Agni-01 multicenter study. Additional details may be found at using identifier: NCT06060613. About OBX-115 Obsidian's lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian's proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. Obsidian is investigating OBX-115 in the phase 1/2 Agni-01 multicenter trial in patients with advanced solid tumors (NCT06060613). About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian's proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. For more information, please visit and follow us on LinkedIn.
